DE69841261D1 - Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenz - Google Patents

Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenz

Info

Publication number
DE69841261D1
DE69841261D1 DE69841261T DE69841261T DE69841261D1 DE 69841261 D1 DE69841261 D1 DE 69841261D1 DE 69841261 T DE69841261 T DE 69841261T DE 69841261 T DE69841261 T DE 69841261T DE 69841261 D1 DE69841261 D1 DE 69841261D1
Authority
DE
Germany
Prior art keywords
genetically modified
tumored
target bacteria
reduced virulence
mutant salmonella
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69841261T
Other languages
English (en)
Inventor
David Bermudes
Kenneth B Low
Martina Ittensohn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Vion Pharmaceuticals Inc
Original Assignee
Yale University
Vion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, Vion Pharmaceuticals Inc filed Critical Yale University
Priority claimed from PCT/US1998/018701 external-priority patent/WO1999013053A1/en
Application granted granted Critical
Publication of DE69841261D1 publication Critical patent/DE69841261D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/879—Salmonella
DE69841261T 1997-09-10 1998-09-09 Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenz Expired - Lifetime DE69841261D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/926,636 US6080849A (en) 1997-09-10 1997-09-10 Genetically modified tumor-targeted bacteria with reduced virulence
US09/149,832 US6447784B1 (en) 1997-09-10 1998-09-08 Genetically modified tumor-targeted bacteria with reduced virulence
PCT/US1998/018701 WO1999013053A1 (en) 1997-09-10 1998-09-09 Genetically modified tumor-targeted bacteria with reduced virulence

Publications (1)

Publication Number Publication Date
DE69841261D1 true DE69841261D1 (de) 2009-12-10

Family

ID=25453492

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69841261T Expired - Lifetime DE69841261D1 (de) 1997-09-10 1998-09-09 Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenz

Country Status (5)

Country Link
US (5) US6080849A (de)
KR (1) KR20010015577A (de)
AT (1) ATE447005T1 (de)
DE (1) DE69841261D1 (de)
ZA (1) ZA988289B (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997881A (en) * 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
US6207648B1 (en) * 1997-07-24 2001-03-27 Trustees Of Boston University Methods of using cytochrome P450 reductase for the enhancement of P450-based anti-cancer gene therapy
EP1012232B1 (de) * 1997-09-10 2009-10-28 Vion Pharmaceuticals, Inc. Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenz
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
CN1420783A (zh) * 1999-10-04 2003-05-28 维昂药品公司 用于将效应分子定向递送至肿瘤的组合物及方法
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
CA2342040C (en) * 2000-09-21 2012-07-10 Kyowa Hakko Kogyo Co., Ltd. Anaerobic bacterium as a drug for cancer gene therapy
US7396822B2 (en) 2001-05-24 2008-07-08 Vaxiion Therapeutics, Inc. Immunogenic minicells and methods of use
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
EP1281767A3 (de) 2001-07-31 2003-05-28 Aladar A. Szalay Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren
US7015027B1 (en) 2001-11-20 2006-03-21 Mds (Canada) Inc. Radiation therapy by accumulation of therapeutic radionuclides in tumor-targeting bacteria
WO2003063593A1 (en) * 2002-01-28 2003-08-07 Vion Pharmaceuticals, Inc. Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent
US20030224369A1 (en) * 2002-02-25 2003-12-04 Surber Mark W. Reverse screening and target identification with minicells
US20030224444A1 (en) * 2002-02-25 2003-12-04 Sabbadini Roger A. Antibodies to native conformations of membrane proteins
US20030207833A1 (en) * 2002-02-25 2003-11-06 Neil Berkley Pharmaceutical compositions with minicells
US20040005700A1 (en) * 2002-05-28 2004-01-08 Surber Mark W. Poroplasts
EP1369491A1 (de) * 2002-06-05 2003-12-10 Aladar A. Szalay Lichtemittierende Mikroorganismen und Zellen für die Diagnose und Therapie von Krankheiten assoziiert mit Wunden oder entzündetem Gewebe
US20030228261A1 (en) * 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
AU2004289953B2 (en) 2003-06-18 2008-09-25 Genelux Corporation Modified recombinant vaccina viruses and other microorganisms, uses thereof
US20070134214A1 (en) * 2003-08-13 2007-06-14 Feng Xu Inactivated host cell delivery of polynucleotides encoding immunogens
US7390646B2 (en) * 2003-09-17 2008-06-24 The Regents Of The University Of California Bacterial vectors and methods of use thereof
US20050112097A1 (en) * 2003-11-26 2005-05-26 Hinton Golden S. Method for the treatment of cancer
US20070298012A1 (en) * 2003-12-16 2007-12-27 Ivan King Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules
WO2006055024A2 (en) * 2004-04-05 2006-05-26 Vaxiion Therapeutics, Inc. Minicells as vaccines
US20050244375A1 (en) * 2004-04-29 2005-11-03 Leonard Arnold S Composition and method of cancer treatment
BRPI0510115B1 (pt) 2004-05-21 2022-09-27 The Regents Of The University Of California Método para produzir um isoprenóide ou precursor de isoprenóide através de uma via de mevalonato em escherichia coli e célula hospedeira geneticamente modificada que os produz
US20060003454A1 (en) * 2004-07-02 2006-01-05 Conjugon, Inc. Non-dividing donor cells for gene transfer
SG158077A1 (en) 2004-11-24 2010-01-29 Anaeropharma Science Inc Novel shuttle vector
WO2006109619A1 (ja) * 2005-04-08 2006-10-19 Anaeropharma Science Inc. ５－フルオロウラシル耐性菌およびその作製方法
US20060270040A1 (en) * 2005-05-26 2006-11-30 Conjugon, Inc. Compositions and methods for treating tissue
ZA200800889B (en) 2005-07-05 2009-09-30 Univ California Polynucleotides encoding isoprenoid modifying enzymes and methods of use thereof
US7935505B2 (en) * 2006-05-24 2011-05-03 Scarab Genomics, Llc Plasmid DNA preparations and methods for producing same
AU2007267033B2 (en) 2006-05-26 2012-05-24 Amyris, Inc. Production of isoprenoids
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
DK3020799T3 (da) 2006-09-26 2020-09-21 Amyris Biotechnologies Inc Fremstilling af isoprenoider og isoprenoid-prækursorer
US7998461B2 (en) * 2007-11-15 2011-08-16 University Of Massachusetts Salmonella cancer therapeutics and related therapeutic methods
WO2009126189A1 (en) 2008-01-11 2009-10-15 Genelux Corporation Methods and compositions for detection of bacteria and treatment of diseases and disorders
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US20100330607A1 (en) * 2009-06-24 2010-12-30 Photoswitch Biosciences, Inc. Photoswitch-enabled ion channel assay system
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
EA024121B9 (ru) 2010-05-10 2017-01-30 Дзе Реджентс Ов Дзе Юниверсити Ов Калифорния Композиции эндорибонуклеаз и способы их использования
WO2012008860A2 (en) 2010-07-16 2012-01-19 Auckland Uniservices Limited Bacterial nitroreductase enzymes and methods relating thereto
JP6199746B2 (ja) 2011-02-15 2017-09-20 バキシオン セラピューティクス，リミテッド ライアビリティ カンパニー 抗体およびＦｃ含有標的化分子に基づく生理活性分子の標的送達のための細菌ミニ細胞による治療用組成物および方法
US8859256B2 (en) 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
JP6406581B2 (ja) 2011-12-16 2018-10-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー オプシンポリペプチドおよびその使用法
WO2013128288A1 (en) * 2012-02-27 2013-09-06 Thelial Technologies S.A. Monomeric bacterial actin adp-ribosyltransferases as cancer chemotherapeutics
US20130280170A1 (en) 2012-04-20 2013-10-24 Aladar A. Szalay Imaging methods for oncolytic virus therapy
US9127284B2 (en) 2012-05-04 2015-09-08 The University Of Hong Kong Modified bacteria and their uses thereof for the treatment of cancer or tumor
AU2013290424B2 (en) 2012-07-19 2018-01-25 Redwood Bioscience, Inc. Antibody specific for CD22 and methods of use thereof
CN104736185B (zh) 2012-08-16 2018-03-20 埃匹瑞恩股份有限公司 治疗Tau病变的方法
CA3124553A1 (en) 2012-10-25 2014-05-01 Bioverativ Usa Inc. Anti-complement c1s antibodies and uses thereof
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
RS60883B1 (sr) 2013-06-10 2020-11-30 Ipierian Inc Metodi lečenja tauopatije
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
EP3581580A1 (de) 2014-03-28 2019-12-18 The Board of Trustees of the Leland Stanford Junior University Manipulierte lichtaktivierte anionenkanalproteine und verfahren zur verwendung davon
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
KR20180029953A (ko) 2015-03-31 2018-03-21 엑셀리겐 사이언티픽, 인코포레이티드 세포 또는 유기체의 게놈으로의 ＤＮＡ 서열의 표적화 혼입을 위한 Ｃａｓ 9 레트로바이러스 인테그라제 시스템 및 Ｃａｓ 9 재조합효소 시스템
LT3280440T (lt) 2015-04-06 2023-02-27 Bioverativ Usa Inc. Humanizuoti antikūnai prieš c1s ir jų panaudojimo būdai
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
AU2016316730B2 (en) 2015-09-02 2023-05-25 Immutep S.A.S. Anti-LAG-3 Antibodies
AU2017246794A1 (en) 2016-04-04 2018-10-25 Genzyme Corporation Anti-complement factor Bb antibodies and uses thereof
IL265957B2 (en) 2016-10-12 2024-04-01 Bioverativ Usa Inc Anti-C1S antibodies and methods of using them
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018200888A1 (en) 2017-04-27 2018-11-01 Regents Of The University Of California Microorganisms and methods for producing cannabinoids and cannabinoid derivatives
CA3069523A1 (en) 2017-07-11 2019-01-17 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
TWI823868B (zh) 2017-10-11 2023-12-01 美商生物維瑞提夫美國公司 誘導補體活性之方法
KR20210032928A (ko) 2018-03-08 2021-03-25 뉴 아틀라스 바이오테크놀로지스 엘엘씨 트립타민의 생산 방법
EP3820992A2 (de) 2018-07-11 2021-05-19 Actym Therapeutics, Inc. Manipulierte immunstimulierende bakterienstämme und verwendungen davon
EP3844276A2 (de) 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Manipulierte immunstimulierende bakterienstämme und verwendungen davon
EP3931210A1 (de) 2019-02-27 2022-01-05 Actym Therapeutics, Inc. Zur besiedlung von tumoren, tumorresidenten immunzellen und der mikroumgebung des tumors entwickelte immunstimulatorische bakterien
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US20220204627A1 (en) 2019-04-02 2022-06-30 Kenjockety Biotechnology, Inc. Efflux Pump-Cancer Antigen Multi-Specific Antibodies and Compositions, Reagents, Kits and Methods Related Thereto
IL292836A (en) 2019-11-12 2022-07-01 Actym Therapeutics Inc Platforms for administering bacteria that stimulate the immune system and their use for administering therapeutic products
WO2021113736A1 (en) 2019-12-05 2021-06-10 Massachusetts Institute Of Technology Single-domain antibody to chloramphenicol
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CA3182969A1 (en) 2020-06-04 2021-12-09 Kenjockety Biotechnology, Inc. Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
CA3191433A1 (en) 2020-08-12 2022-02-17 Actym Therapeutics, Inc. Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
WO2023086796A2 (en) 2021-11-09 2023-05-19 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
WO2023114658A1 (en) 2021-12-13 2023-06-22 Kenjockety Biotechnology, Inc. Anti-abcb1 antibodies
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies
WO2023192869A1 (en) 2022-03-28 2023-10-05 University Of Massachusetts Antigen delivering salmonella for use as a tumor homing beacon to refocus preexisting, vaccine generated t cells to combat cancer

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US29043A (en) * 1860-07-10 Improvement in cultivators
JPS57142256A (en) 1981-02-25 1982-09-02 Kao Corp Sanitary napkin
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
EP0142641B1 (de) * 1983-09-26 1991-01-16 Udo Dr. Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
CA1321962C (en) 1985-03-20 1993-09-07 Aizo Matsushiro Dental caries preventive preparations and method for preparing said preparations
JPH0696538B2 (ja) 1985-12-19 1994-11-30 株式会社アドバンス 抗発癌剤
JPH0761950B2 (ja) 1986-10-17 1995-07-05 塩野義製薬株式会社 抗腫瘍剤
DE3735381A1 (de) 1987-03-31 1989-05-03 Boehringer Mannheim Gmbh Rekombinante dna zur reprimierbaren und induzierbaren expression von fremdgenen
GB8730037D0 (en) 1987-12-23 1988-02-03 Wellcome Found Vaccines
JPH01180830A (ja) 1988-01-11 1989-07-18 Kayaku:Kk 抗腫瘍剤
EP0338679A3 (de) 1988-03-24 1991-03-06 Genentech, Inc. Tumor Necrosis Faktor zur Behandlung von Blasenkrebs
JPH0284172A (ja) 1988-07-21 1990-03-26 Smithkline Beckman Corp 異種遺伝子の発現能を有し、組換え型ワクチンとして有用なサルモネラ形質転換体
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
JPH0376580A (ja) * 1989-08-17 1991-04-02 Japan Tobacco Inc 大腸菌発現ベクターとそれを利用した抗ウイルス性タンパク質の製造方法
EP0500699B1 (de) 1989-11-03 1998-06-10 Washington University Kreuzschützende salmonella impfstoffe
US5830702A (en) * 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
JP3367950B2 (ja) * 1990-12-18 2003-01-20 ザ ジェネラル ホスピタル コーポレーション 改良されたワクチン
US5695983A (en) * 1990-12-18 1997-12-09 The General Hospital Corporation Salmonella vaccines
CA2099841C (en) 1991-03-05 2003-02-25 Ian G. Charles Expression of recombinant proteins in attenuated bacteria
IL101410A0 (en) 1992-03-29 1992-11-15 Era Masis Ltd Formulation for the treatment of cancer
IL101409A0 (en) * 1992-03-29 1992-11-15 Era Masis Ltd Method for the early diagnosis of cancer
JPH06298657A (ja) 1993-04-15 1994-10-25 Nippon Shoji Kk 免疫強化剤
WO1995005832A1 (fr) 1993-08-25 1995-03-02 Otsuka Pharmaceutical Factory, Inc. Analeptique des fonctions cardiaques
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
JPH09504518A (ja) 1993-10-06 1997-05-06 アメリカ合衆国 負の選択マーカーおよびサイトカインをコード化する遺伝子を用いる腫瘍細胞の遺伝子転換による腫瘍の治療
IT1270123B (it) * 1994-10-05 1997-04-28 Dompe Spa Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
US6051237A (en) * 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US5877159A (en) 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US6150170A (en) * 1998-05-03 2000-11-21 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US5705151A (en) * 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
AU731061B2 (en) 1995-09-06 2001-03-22 Department Of The Army, U.S. Government Bacterial delivery system
US5824538A (en) 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
GB9521568D0 (en) 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
WO1997018225A1 (en) 1995-11-14 1997-05-22 The General Hospital Corporation Salmonella secreted proteins and uses thereof
US5997881A (en) * 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
US6887483B2 (en) * 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
WO1997025061A1 (en) * 1996-01-09 1997-07-17 Bristol-Myers Squibb Company De-myristolated lipopolysaccharide of gram-negative bacteria
EA002985B1 (ru) 1996-02-16 2002-12-26 Жансен Фармасетика Н.В. Очищающая композиция для тела и волос, в частности шампунь, и способ ее получения
ATE229805T1 (de) 1996-05-10 2003-01-15 Upjohn Co Topische verabreichung von premafloxacin zur behandlung von systemischen bakteriellen erkrankungen
GB9621091D0 (en) * 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
TW373083B (en) 1996-12-20 1999-11-01 Corning Inc Reflective coupling array for optical waveguide
AU5873498A (en) 1997-01-30 1998-08-25 Imperial College Of Science, Technology And Medicine Mutant (msbb) or (htrb) genes
WO1998044131A1 (en) * 1997-03-28 1998-10-08 Walter Reed Army Institute Of Research Antimicrobial mediated bacterial dna delivery
US6537558B2 (en) * 1997-03-31 2003-03-25 Megan Health, Inc. Methods of producing and using virulence attenuated poxR mutant bacteria
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
EP1012232B1 (de) 1997-09-10 2009-10-28 Vion Pharmaceuticals, Inc. Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenz
US6143551A (en) * 1997-12-29 2000-11-07 Schering Aktiengesellschaft Delivery of polypeptide-encoding plasmid DNA into the cytosol of macrophages by attenuated listeria suicide bacteria
US6593592B1 (en) * 1999-01-29 2003-07-15 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device having thin film transistors
CN1420783A (zh) 1999-10-04 2003-05-28 维昂药品公司 用于将效应分子定向递送至肿瘤的组合物及方法
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
EP1281767A3 (de) * 2001-07-31 2003-05-28 Aladar A. Szalay Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren
US20070298012A1 (en) * 2003-12-16 2007-12-27 Ivan King Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules

Also Published As

Publication number Publication date
ZA988289B (en) 1999-03-22
US20030170276A1 (en) 2003-09-11
US20070009489A1 (en) 2007-01-11
KR20010015577A (ko) 2001-02-26
US7514089B2 (en) 2009-04-07
US6923972B2 (en) 2005-08-02
US20020026655A1 (en) 2002-02-28
US6447784B1 (en) 2002-09-10
US6080849A (en) 2000-06-27
US6475482B1 (en) 2002-11-05
ATE447005T1 (de) 2009-11-15

Similar Documents

Publication Publication Date Title
DE69841261D1 (de) Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenz
HK1033956A1 (en) Genetically modified tumor-targeted bacteria with reduced virulence
DE69631423D1 (de) Chinolone und deren therapeutische verwendung
FI964681A0 (fi) Ihmisperäiset Lactobacillus-kannat, niitä sisältävät valmisteet ja niiden käytöt
WO1993008259A3 (en) Inhibitors of dipeptidyl-aminopeptidase type IV
HUP9801826A2 (hu) HER-2/neu-fehérje intracelluláris doménje, és alkalmazása malignitások megelőzésére és kezelésére
DK1005353T3 (da) Farmaceutisk præparat omfattende Lactobacillus casei rhamnosus
FI961621A0 (fi) Proteiini:farnesyylitranseraasin substituoidut tetra- ja pentapeptidi-inhibiittorit
MX9800922A (es) Quinolonas y su uso terapeutico.
BG102708A (en) 4-aminopyrimidine derivatives, medicamentous preparations containing them, their application and method for their preparation
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
BR9805544C1 (pt) Uso de um composto.
WO1996035784A3 (de) Chromatin-regulatorgene
DE69322166D1 (de) Prüfung auf ein vielfache resistenz gegen antibiotika verursachendes operon
ES2184861T3 (es) Compuestos peptidicos inhibidores de la liberacion de la metaloproteinasa y del tnf y su utilizacion terapeutica.
ES2187648T3 (es) Metodo para la administracion de farmacos para terapia genica.
HK1024265A1 (en) Mutants of streptococcal toxin c and methods of use
PT1294874E (pt) Variantes de cd154 e as suas utilizacoes
EA200200704A1 (ru) Ослабленные микроорганизмы для лечения инфекции
NZ515727A (en) Aminotetralin derivative for the therapy of cardiovascular diseases
AU2002249173A1 (en) Phosphorylated glyoxalase i and its use
IT1276454B1 (it) Metodo per la diagnosi di infezioni helycobacter pylori e relativo corredo diagnostico.
ATE214911T1 (de) Verwendung von mikroorganismen extrakten in kosmetischen oder pharmazeutischen zusammensetzungen
NZ515912A (en) Fimbrial proteins
WO2001028573A3 (en) Monocyte conditioned medium for cancer treatment

Legal Events

Date Code Title Description
8364 No opposition during term of opposition